Overview
SCIENTIFIC SCORE
Questionable
Based on 6 Researches
6.3
USERS' SCORE
Moderately Good
Based on 72 Reviews
7.9
Supplement Facts
Serving Size: 1 Veg Capsule
Amount Per Serving
%DV
Vitamin K2(as Menaquinone-7) (MK-7 ) (MenaQ7®)
100 mcg
**
Top Medical Research Studies
9
Vitamin K1 reduces coronary calcifications
We aimed to determine how vitamin K1 affects coronary artery calcifications in patients undergoing hemodialysis. In our study with 60 participants, we compared the effects of intravenous vitamin K1 against a placebo over 12 months.
The results showed that vitamin K1 significantly slowed the progression of coronary artery calcifications by 55%, compared to the placebo group. This finding suggests vitamin K1 may offer an important benefit in managing heart health for those with chronic kidney disease.
The results showed that vitamin K1 significantly slowed the progression of coronary artery calcifications by 55%, compared to the placebo group. This finding suggests vitamin K1 may offer an important benefit in managing heart health for those with chronic kidney disease.
Read More
7
Real-world effectiveness of blood thinners
We explored how well the outcomes of landmark trials for two blood thinners—apixaban and rivaroxaban—hold up in real-world atrial fibrillation (AF) patients. By examining data from the GARFIELD-AF registry, we found that patients on these treatments had similar results in preventing strokes, bleeding, and overall mortality when compared to those on vitamin K antagonists.
While apixaban showed promising results, rivaroxaban had more mixed findings, yet overall, the effectiveness and safety were largely in line with the original trials. This suggests that these medications can be appropriately used in everyday medical practice.
While apixaban showed promising results, rivaroxaban had more mixed findings, yet overall, the effectiveness and safety were largely in line with the original trials. This suggests that these medications can be appropriately used in everyday medical practice.
Read More
4
Vitamin K antagonists raise mortality risk
We analyzed data from a study involving patients who underwent mitral valve repair and had atrial fibrillation, comparing the effects of direct oral anticoagulants to vitamin K antagonists (VKAs).
Surprisingly, we found that both treatments led to similar rates of serious complications, like strokes or bleeding. However, those on VKAs showed a significantly higher overall mortality. This suggests that while both anticoagulants may work similarly for immediate outcomes, VKAs might come with increased risks for longer-term survival. Further research is needed to clarify the best options for these patients.
Surprisingly, we found that both treatments led to similar rates of serious complications, like strokes or bleeding. However, those on VKAs showed a significantly higher overall mortality. This suggests that while both anticoagulants may work similarly for immediate outcomes, VKAs might come with increased risks for longer-term survival. Further research is needed to clarify the best options for these patients.
Read More
Most Useful Reviews
8.5
Reduces heart disease risk
140 people found this helpful
I recommend a daily dose of 180 mcg of vitamin K2 (MK-7) for postmenopausal women and older men. It helps in calcium absorption, reduces coronary artery calcification, and overall mortality linked to heart disease. Statin users should consider K2 supplements, as statins lower vitamin K levels.
Read More
9
Supports calcium regulation
48 people found this helpful
Vitamin K2 is key for proper calcium absorption, directing it to bones instead of arteries, thus helping prevent heart disease.
Read More
9
Stops nosebleeds
37 people found this helpful
After taking MK-7, my long-standing nosebleeds ceased. I appreciate that vitamin K2 also supports heart health and bone strength.
Read More
Medical Researches
SCIENTIFIC SCORE
Questionable
Based on 6 Researches
6.3
- All Researches
9
Vitamin K1 reduces coronary calcifications
We aimed to determine how vitamin K1 affects coronary artery calcifications in patients undergoing hemodialysis. In our study with 60 participants, we compared the effects of intravenous vitamin K1 against a placebo over 12 months.
The results showed that vitamin K1 significantly slowed the progression of coronary artery calcifications by 55%, compared to the placebo group. This finding suggests vitamin K1 may offer an important benefit in managing heart health for those with chronic kidney disease.
The results showed that vitamin K1 significantly slowed the progression of coronary artery calcifications by 55%, compared to the placebo group. This finding suggests vitamin K1 may offer an important benefit in managing heart health for those with chronic kidney disease.
Read More
9
We analyzed a study comparing two anticoagulation options—direct oral anticoagulants (DOACs) and vitamin K antagonists (VKAs)—in patients with non-valvular atrial fibrillation who faced blood clots despite previous treatment.
Our findings reveal that those on DOACs had significantly fewer cardioembolic events and complications following left atrial appendage closure.
In contrast, patients on VKAs did not show the same benefit, which suggests that DOACs may be a more effective option for ongoing treatment in these cases.
Our findings reveal that those on DOACs had significantly fewer cardioembolic events and complications following left atrial appendage closure.
In contrast, patients on VKAs did not show the same benefit, which suggests that DOACs may be a more effective option for ongoing treatment in these cases.
Read More
7
Real-world effectiveness of blood thinners
We explored how well the outcomes of landmark trials for two blood thinners—apixaban and rivaroxaban—hold up in real-world atrial fibrillation (AF) patients. By examining data from the GARFIELD-AF registry, we found that patients on these treatments had similar results in preventing strokes, bleeding, and overall mortality when compared to those on vitamin K antagonists.
While apixaban showed promising results, rivaroxaban had more mixed findings, yet overall, the effectiveness and safety were largely in line with the original trials. This suggests that these medications can be appropriately used in everyday medical practice.
While apixaban showed promising results, rivaroxaban had more mixed findings, yet overall, the effectiveness and safety were largely in line with the original trials. This suggests that these medications can be appropriately used in everyday medical practice.
Read More
5
Vitamin K antagonists: outcomes assessed
We investigated the impact of vitamin K antagonists (VKA) on patients with atrial fibrillation (AF). Our study included 1,350 patients who received VKA for at least a year, tracking various outcomes like cardiovascular death and thromboembolic events.
Interestingly, while we noted predictors for these clinical outcomes—like previous thromboembolism or bleeding—no significant improvement in heart disease was directly linked to vitamin K treatment itself. Instead, factors such as age and kidney function played crucial roles in determining patient outcomes.
Interestingly, while we noted predictors for these clinical outcomes—like previous thromboembolism or bleeding—no significant improvement in heart disease was directly linked to vitamin K treatment itself. Instead, factors such as age and kidney function played crucial roles in determining patient outcomes.
Read More
4
Vitamin K antagonists raise mortality risk
We analyzed data from a study involving patients who underwent mitral valve repair and had atrial fibrillation, comparing the effects of direct oral anticoagulants to vitamin K antagonists (VKAs).
Surprisingly, we found that both treatments led to similar rates of serious complications, like strokes or bleeding. However, those on VKAs showed a significantly higher overall mortality. This suggests that while both anticoagulants may work similarly for immediate outcomes, VKAs might come with increased risks for longer-term survival. Further research is needed to clarify the best options for these patients.
Surprisingly, we found that both treatments led to similar rates of serious complications, like strokes or bleeding. However, those on VKAs showed a significantly higher overall mortality. This suggests that while both anticoagulants may work similarly for immediate outcomes, VKAs might come with increased risks for longer-term survival. Further research is needed to clarify the best options for these patients.
Read More
User Reviews
USERS' SCORE
Moderately Good
Based on 72 Reviews
7.9
- All Reviews
- Positive Reviews
- Negative Reviews
8.5
Reduces heart disease risk
140 people found this helpful
I recommend a daily dose of 180 mcg of vitamin K2 (MK-7) for postmenopausal women and older men. It helps in calcium absorption, reduces coronary artery calcification, and overall mortality linked to heart disease. Statin users should consider K2 supplements, as statins lower vitamin K levels.
Read More
9
Supports calcium regulation
48 people found this helpful
Vitamin K2 is key for proper calcium absorption, directing it to bones instead of arteries, thus helping prevent heart disease.
Read More
9
Stops nosebleeds
37 people found this helpful
After taking MK-7, my long-standing nosebleeds ceased. I appreciate that vitamin K2 also supports heart health and bone strength.
Read More
7.5
Prevents heart issues
18 people found this helpful
If you're supplementing with D3, it's essential to take K2. It directs calcium into bones, preventing heart complications from excess calcium.
Read More
9
Reduces coronary risk
16 people found this helpful
K2 MK-7 enhances artery elasticity and may reduce mortality rates. At a dosage of 180 mcg per day, it’s recommended especially for postmenopausal women and those on statins. It significantly lowers heart disease risk by promoting calcium absorption and preventing arterial calcification.
Read More
Frequently Asked Questions
9
Regular heartbeat noted
7 people found this helpful
After taking K2, LactoBif 30, and ubiquinol for nearly six months, my irregular heartbeat has improved remarkably. Although I’m unsure which supplement made the difference, I believe these quality ingredients have significantly enhanced my heart health.
9
Improved breathing
5 people found this helpful
I have been taking MK-7 for five months to ensure calcium is deposited in my bones instead of my arteries. Remarkably, I can now breathe fully without the previous tightness in my chest, with about 90% of the restriction gone. This has motivated me to take my health more seriously and follow Linus Pauling's Heart Protocol.
9
Artery calcification reduction
8 people found this helpful
I've used Now Foods MK-7 for 2 years. At 73, my heart condition remains good as it helps remove artery calcification. My nails have changed from brittle to strong, and my hair has become thicker.
9
Stops nosebleeds
37 people found this helpful
After taking MK-7, my long-standing nosebleeds ceased. I appreciate that vitamin K2 also supports heart health and bone strength.
9
Bone health support
4 people found this helpful
My doctor advised taking vitamin D3, magnesium, calcium, and vitamin K2 for osteoporosis, as vitamin K2 directs calcium to the bones, thus helping to prevent calcium accumulation in blood vessels.
7.5
Reduces arterial stiffness
3 people found this helpful
Vitamin K2 enhances calcium absorption, reducing the risk of osteoporosis and arterial stiffness, which is essential for preventing heart disease.
8.5
Reduces heart disease risk
140 people found this helpful
I recommend a daily dose of 180 mcg of vitamin K2 (MK-7) for postmenopausal women and older men. It helps in calcium absorption, reduces coronary artery calcification, and overall mortality linked to heart disease. Statin users should consider K2 supplements, as statins lower vitamin K levels.
9
Prevents heart disease
13 people found this helpful
Vitamin K2, in the MK7 formula, should be taken with vitamin D3 to ensure calcium is absorbed in bones rather than soft tissues, protecting against vascular calcification. This product is reasonably priced, and vitamin K2 is vital for overall health. The risk of fractures is substantially reduced with adequate levels of K2, which also aids in preventing heart disease.
7.5
Prevents heart issues
18 people found this helpful
If you're supplementing with D3, it's essential to take K2. It directs calcium into bones, preventing heart complications from excess calcium.
5
Vitamin K antagonists: outcomes assessed
We investigated the impact of vitamin K antagonists (VKA) on patients with atrial fibrillation (AF). Our study included 1,350 patients who received VKA for at least a year, tracking various outcomes like cardiovascular death and thromboembolic events.
Interestingly, while we noted predictors for these clinical outcomes—like previous thromboembolism or bleeding—no significant improvement in heart disease was directly linked to vitamin K treatment itself. Instead, factors such as age and kidney function played crucial roles in determining patient outcomes.
Interestingly, while we noted predictors for these clinical outcomes—like previous thromboembolism or bleeding—no significant improvement in heart disease was directly linked to vitamin K treatment itself. Instead, factors such as age and kidney function played crucial roles in determining patient outcomes.
4
We examined the effectiveness and safety of anti-thrombotic therapy after surgical mitral valve repair (MVr). Our scoping review analyzed 11 studies, including randomized controlled trials and cohort studies, which assessed various therapies like vitamin K antagonists. The results were inconsistent, showing that some therapies had no significant difference in reducing thromboembolic events, while bleeding rates varied widely. Due to design limitations in existing literature, we highlighted the need for a well-structured future study to provide clearer guidance on anti-thrombotic management in MVr patients.
9
Vitamin K1 reduces coronary calcifications
We aimed to determine how vitamin K1 affects coronary artery calcifications in patients undergoing hemodialysis. In our study with 60 participants, we compared the effects of intravenous vitamin K1 against a placebo over 12 months.
The results showed that vitamin K1 significantly slowed the progression of coronary artery calcifications by 55%, compared to the placebo group. This finding suggests vitamin K1 may offer an important benefit in managing heart health for those with chronic kidney disease.
The results showed that vitamin K1 significantly slowed the progression of coronary artery calcifications by 55%, compared to the placebo group. This finding suggests vitamin K1 may offer an important benefit in managing heart health for those with chronic kidney disease.
9
We analyzed a study comparing two anticoagulation options—direct oral anticoagulants (DOACs) and vitamin K antagonists (VKAs)—in patients with non-valvular atrial fibrillation who faced blood clots despite previous treatment.
Our findings reveal that those on DOACs had significantly fewer cardioembolic events and complications following left atrial appendage closure.
In contrast, patients on VKAs did not show the same benefit, which suggests that DOACs may be a more effective option for ongoing treatment in these cases.
Our findings reveal that those on DOACs had significantly fewer cardioembolic events and complications following left atrial appendage closure.
In contrast, patients on VKAs did not show the same benefit, which suggests that DOACs may be a more effective option for ongoing treatment in these cases.
References
- Liporace IL, Oliveira GBF, Alves LBO, Galassi NM, Jeronimo AD, et al. Incidence and Predictors of Clinical Outcomes in Patients with Valvular and Nonvalvular Atrial Fibrillation Using Vitamin K Antagonists. Arq Bras Cardiol. 2025;122:e20240147. doi:10.36660/abc.20240147
- Schipper JH, Sommer AS, Nies RJ, Metze C, Meertens MM, et al. Direct Oral Anticoagulants Versus Vitamin K Antagonists After Mitral Valve Transcatheter Edge-to-Edge Repair in Patients With Atrial Fibrillation: A Single-Center Observational Study. J Am Heart Assoc. 2025;14:e038834. doi:10.1161/JAHA.124.038834
- Babadagli HE, Ye J, Chen J, Turgeon R, Wang EH. Efficacy and safety of anti-thrombotic therapy after surgical mitral valve repair: a scoping review. Open Heart. 2025;12. doi:10.1136/openhrt-2024-003158
- Himmelreich JCL, Virdone S, Camm AJ, Pieper K, Harskamp RE, et al. Emulation of ARISTOTLE and ROCKET AF trials in real-world atrial fibrillation patients results in similar efficacy and safety as original landmark trials: insights from the GARFIELD-AF registry. Open Heart. 2025;12. doi:10.1136/openhrt-2024-002966
- Macias-Cervantes HE, Ocampo-Apolonio MA, Guardado-Mendoza R, Baron-Manzo M, Pereyra-Nobara TA, et al. Effect of vitamin K1 supplementation on coronary calcifications in hemodialysis patients: a randomized controlled trial. J Nephrol. 2025;38:511. doi:10.1007/s40620-024-02154-9
- Preda A, Falasconi G, Melillo F, Margonato D, Posteraro GA, et al. Left atrial appendage closure in patients with failure of anticoagulation therapy: A multicenter comparative study on the hybrid strategy using DOACs and VKAs. Int J Cardiol. 2025;421:132875. doi:10.1016/j.ijcard.2024.132875
